Treatment Interruption and Regimen Change in Firstgeneration versus Second-generation Tyrosine Kinase Inhibitors used as First-line Therapy for Chronic Myeloid Leukemia

by Melea A. Ward, Gang Fang, Kristy L. Richards, Christine M. Walko, Stephanie R. Earnshaw, Laura E. Happe, Susan J. Blalock

Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With V600E-Mutated Gliomas

by Michael J. Fusco PharmD, Yolanda Piña MD, Robert J. Macaulay MD, Solmaz Sahebjam MD, Peter A. Forsyth MD, Edwin Peguero MD, Christine M. Walko PharmD
Published 2021-09-01